

## Chapter 7: Drugs

### References

1. Gao L, Maidment I, Matthews FE, Robinson L, Brayne C. Medication usage change in older people (65+) in England over 20 years: findings from CFAS I and CFAS II. *Age Ageing*. 2018;47(2):220-225. <http://dx.doi.org/10.1093/ageing/afx158>.
2. Addiction Crisis <http://www.bbc.co.uk/news/uk-england-43304375>.
3. Academic Emergency Medicine. 2018.
4. Maher R, Hanlon J HE. Clinical Consequences of Polypharmacy in Elderly Robert. *Expert Opin Drug Saf*. 2014;13(1):1-11. doi:10.1517/14740338.2013.827660.Clinical.
5. Forster K. Prescription drug addiction “to overtake heroin use” in UK. UK Addiction Treatment Centres. 2017.
6. Quora. Is it a bad thing that pharmaceutical companies spend more on marketing than on research?
7. Tae Kim. “ Is curing patients a sustainable business model?” @fisrtadopter. 2018.
8. Kluger BJ. Is Drug-Company Money Tainting Medical Education? TIME Friday, Mar 06, 2009.
9. <https://edition.cnn.com/2018/03/11/health/prescription-opioid-payments-eprise/index.html>.
10. Co-Chairs of the Medical Students Committee ..... ongoing student campaign groups including Queen Mary ... Motion by LIVERPOOL

- MEDICAL SCHOOL. [www.bma.org.uk](http://www.bma.org.uk) 2017. In: This Conference Notes ..... Council, Health Education England and All Other Relevant Bodies to Include More Teaching on Nutrition.
11. Vu RK and P. The Pharmaceutical Industry's Role in U.S. Medical Education. In-Training. 2016.
  12. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet*. March 2018. doi:10.1016/S0140-6736(17)32802-7.
  13. Joyce Cavaye ( Open University). The Conversation.
  14. Cartwright C, Gibson K, Read J, Cowan O, Dehar T. Long-term antidepressant use: patient perspectives of benefits and adverse effects. *Patient Prefer Adherence*. 2016;10:1401-1407. doi:10.2147/PPA.S110632.
  15. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Ther Adv Drug Saf*. 2014;5(6):229-241. doi:10.1177/2042098614554919.
  16. Tasnim N, Abulizi N, Pither J, Hart MM, Gibson DL. Linking the gut microbial ecosystem with the environment: Does gut health depend on where we live? *Front Microbiol*. 2017;8(OCT):1-8. doi:10.3389/fmicb.2017.01935.
  17. Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. *J Clin Invest*. 2014;124(10):4212-4218. doi:10.1172/JCI72333.

18. Hoffman KL, Hutchinson DS, Fowler J, et al. Oral microbiota reveals signs of acculturation in Mexican American women. *PLoS One*. 2018;13(4). doi:10.1371/journal.pone.0194100.
19. Vulevic J, Juric A, Tzortzis G, Gibson GR. A Mixture of trans-Galactooligosaccharides Reduces Markers of Metabolic Syndrome and Modulates the Fecal Microbiota and Immune Function of Overweight Adults. *J Nutr*. 2013;143(3):324-331. doi:10.3945/jn.112.166132.
20. Watanabe K, Gilchrist CA, Uddin MJ, et al. Microbiome-mediated neutrophil recruitment via CXCR2 and protection from amebic colitis. *PLoS Pathog*. 2017;13(8):1-20. doi:10.1371/journal.ppat.1006513.
21. Devilbiss DM, Berridge CW. Cognition-Enhancing Doses of Methylphenidate Preferentially Increase Prefrontal Cortex Neuronal Responsiveness. *Biol Psychiatry*. 2018;64(7):626-635. doi:10.1016/j.biopsych.2008.04.037.
22. Kolar D, Keller A, Golfinopoulos M, Cumyn L, Syer C, Hechtman L. Treatment of adults with attention-deficit/hyperactivity disorder. *Neuropsychiatr Dis Treat*. 2008;4(2):389-403. doi:10.2147/NDT.S6985.
23. SA King, MJ Casavant, HA Spiller NH. Pediatric ADHD medication exposures reported to US poison control centers. *Acad Pediatr*. 2018.
24. NICE. Methylphenidate Hydrochloride. <https://bnf.nice.org.uk/drug/methylphenidate-hydrochloride.html>.
25. Gunter MJ, Murphy N, Cross AJ, et al. Coffee drinking and mortality in 10 European countries: A multinational cohort study. *Ann Intern Med*. 2017;167(4):236-247. doi:10.7326/M16-2945.

26. Ale-Agha N. CDKN1B/p27 –New mode of action for caffeine. PLoS Biol. 2018.
27. [https://academic.oup.com/eurheartj/article/38/suppl\\_1/ehx502.1199/4088242](https://academic.oup.com/eurheartj/article/38/suppl_1/ehx502.1199/4088242).
28. Liu R, Guo X, Park Y, et al. Caffeine intake, smoking, and risk of parkinson disease in men and women. Am J Epidemiol. 2012;175(11):1200-1207. doi:10.1093/aje/kwr451.
29. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: A population-based CAIDE study. J Alzheimer's Dis. 2009;16(1):85-91. doi:10.3233/JAD-2009-0920.
30. Yamagata K. Do Coffee Polyphenols Have a Preventive Action on Metabolic Syndrome Associated Endothelial Dysfunctions? An Assessment of the Current Evidence. Antioxidants. 2018;7(2):26. doi:10.3390/antiox7020026.
31. Cowan TE, Palmnas M, Ardell K, et al. Chronic coffee consumption alters gut microbiome: potential mechanism to explain the protective effects of coffee on type 2 diabetes? . Faseb J. 2013;27:951.1.
32. Acheson KJ, Zahorska-Markiewicz B, Pittet P, Anantharaman K, Jéquier E. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Am J Clin Nutr. 1980;33(5):989-997. doi:10.1093/ajcn/33.5.989.
33. Ammon HPT. Biochemical Mechanism of Caffeine Tolerance. Arch Pharm (Weinheim). 1991;324(5):261-267. doi:10.1002/ardp.19913240502.

34. Lafranconi A, Micek A, Galvano F, et al. Coffee decreases the risk of endometrial cancer: A dose–response meta-analysis of prospective cohort studies. *Nutrients*. 2017;9(11). doi:10.3390/nu9111223.
35. Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: A systematic review and dose-response meta-Analysis. *BMJ Open*. 2017;7(5). doi:10.1136/bmjopen-2016-013739.
36. Russell MA. Low-tar medium-nicotine cigarettes: a new approach to safer smoking. *Br Med J*. 1976;1(6023):1430-1433. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1640397/>.
37. Office for National Statistics. Adult smoking habits in the UK: 2016. 2017. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/bulletins/adultsmokinghabitsinngreatbritain/2016>.
38. Office for National Statistics. Alcohol-specific deaths in the UK: registered in 2016. 2017. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/alcoholrelateddeathsintheunitedkingdom/registeredin2016>.
39. Kapelewski CH, Klein DJV and LC. Effect of Monoamine Oxidase Inhibition on Rewarding Effects of Nicotine in Rodents. *Curr Drug Abuse Rev*. 2011;4(2):110-121. doi:<http://dx.doi.org/10.2174/1874473711104020110>.
40. Hoffman AC, Evans SE. Abuse potential of non-nicotine tobacco smoke components: Acetaldehyde, nornicotine, cotinine, and anabasine. *Nicotine Tob Res*. 2013;15(3):622-632. doi:10.1093/ntr/nts192.

41. García-Rodríguez O, Secades-Villa R, Flórez-Salamanca L, Okuda M, Liu S-M, Blanco C. Probability and predictors of relapse to smoking: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *Drug Alcohol Depend.* 2013;132(3):479-485. doi:10.1016/j.drugalcdep.2013.03.008.
42. Tindle HA, Stevenson Duncan M, Greevy RA, et al. Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study. *JNCI J Natl Cancer Inst.* 2018:djy041-djy041. doi:10.1093/jnci/djy041.
43. Shahab L, Goniewicz ML, Blount BC, et al. Nicotine, carcinogen, and toxin exposure in long-Term e-cigarette and nicotine replacement therapy users. *Ann Intern Med.* 2017;166(6):390-400. doi:10.7326/M16-1107.
44. Jonathon Scott. <http://milestogodrugeducation.com/index.html>. 2018.
45. Stewart CJ, Auchtung TA, Ajami NJ, et al. Effects of tobacco smoke and electronic cigarette vapor exposure on the oral and gut microbiota in humans: a pilot study. *PeerJ.* 2018;6:e4693. doi:10.7717/peerj.4693.
46. NHS. New alcohol advice issued. <https://www.nhs.uk/news/food-and-diet/new-alcohol-advice-issued/>. Published 2016.
47. NHS. The risks of drinking too much. <https://www.nhs.uk/Livewell/alcohol/Pages/Effectsofalcohol.aspx>. Published 2016.
48. Connor J, Hall W. Thresholds for safer alcohol use might need lowering. *Lancet.* 2018;391(10129):1460-1461. doi:10.1016/S0140-6736(18)30545-2.

49. Wood AM, Kaptoge S, Butterworth AS, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. *Lancet*. 2018;391(10129):1513-1523. doi:10.1016/S0140-6736(18)30134-X.
50. Stockley CS. Wine consumption, cognitive function and dementias – A relationship? *Nutr Aging*. 2016;3(2-4):125-137. doi:10.3233/NUA-150055.
51. Chiva-Blanch G, Arranz S, Lamuela-Raventos RM, Estruch R. Effects of wine, alcohol and polyphenols on cardiovascular disease risk factors: Evidences from human studies. *Alcohol Alcohol*. 2013;48(3):270-277. doi:10.1093/alcalc/agt007.
52. Topiwala A, Allan CL, Valkanova V, et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. *BMJ*. 2017;j2353. doi:10.1136/bmj.j2353.
53. <https://Digital.Nhs.Uk/Data-and-Information/Publications/Statistical/Statistics-on-Drug-Misuse/2018>.
54. Kozor R, Grieve SM, Buchholz S, et al. Regular cocaine use is associated with increased systolic blood pressure, aortic stiffness and left ventricular mass in young otherwise healthy individuals. *PLoS One*. 2014;9(4):1-8. doi:10.1371/journal.pone.0089710.
55. Buchholz S, Grieve SM, Maher R, Figtree GA. Cocaine-induced myocardial injury seen as multiple mid-wall foci of late enhancement by contrast-enhanced cardiac magnetic resonance imaging. *Eur Heart J*. 2010;31(11):1422. doi:10.1093/eurheartj/ehq036.

56. Qureshi AI, Chaudhry SA, Suri MFK. Cocaine use and the likelihood of cardiovascular and all-cause mortality: data from the Third National Health and Nutrition Examination Survey Mortality Follow-up Study. *J Vasc Interv Neurol.* 2014;7(1):76-82.  
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4051909&tool=pmcentrez&rendertype=abstract>.
  
57. Lader D (Editor). Drug misuse: findings from the 2015/16 Crime Survey for England and Wales. *Statistical Bulletin 07/16.* 2016;(July).  
[https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/462885/drug-misuse-1415.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/462885/drug-misuse-1415.pdf).
  
58. Chalk W. This is what happens if you take too much MDMA. BBC Newsbeat.  
<https://www.nhs.uk/Livewell/drugs/Pages/Drugsoverview.aspx>. Accessed March 21, 2018.
  
59. The effects of drugs. NHS.  
<https://www.nhs.uk/Livewell/drugs/Pages/Drugsoverview.aspx>. Published 2015. Accessed March 21, 2018.
  
60. R. LK, Joy K. Ecstasy (MDMA) and memory function: a meta-analytic update. *Hum Psychopharmacol Clin Exp.* 2007;22(6):381-388.  
doi:10.1002/hup.857.
  
61. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid–Opioid Interaction in Chronic Pain. *Clin Pharmacol Ther.* 2011;90(6):844-851. doi:10.1038/clpt.2011.188.
  
62. Lynch ME, Clark AJ. Cannabis Reduces Opioid Dose in the Treatment of Chronic Non-Cancer Pain. *J Pain Symptom Manage.* 2018;25(6):496-498. doi:10.1016/S0885-3924(03)00142-8.



63. Stockings E, Zagic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. *J Neurol Neurosurg & Psychiatry*. March 2018. <http://jnnp.bmj.com/content/early/2018/02/05/jnnp-2017-317168.abstract>.
  
64. [www.nature.com/articles/s41598-017-17546-0](http://www.nature.com/articles/s41598-017-17546-0).
  
65. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. *Schizophr Bull*. 2016;42(5):1262-1269. doi:10.1093/schbul/sbw003.
  
66. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. *J Psychopharmacol*. 2005;19(2):187-194. doi:10.1177/0269881105049040.
  
67. Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet*. 2007;370(9584):319-328. doi:[https://doi.org/10.1016/S0140-6736\(07\)61162-3](https://doi.org/10.1016/S0140-6736(07)61162-3).
  
68. Myles N, Newall H, Large ON and M. The Association between Cannabis Use and Earlier Age at Onset of Schizophrenia and other Psychoses: Meta-analysis of Possible Confounding Factors. *Curr Pharm Des*. 2012;18(32):5055-5069. doi:<http://dx.doi.org/10.2174/138161212802884816>.
  
69. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. *BMJ*. 2002;325(7374):1195-1198. doi:10.1136/bmj.325.7374.1195.